Skip to main content
ISTH 2023 Main banner
Back

    Benoît Ho-Tin-Noé, PhD

    Research Director
    Université de Paris Descartes, INSERM, Hôpital Bichat, UMR-S1148, F-75000 Paris, France
    Paris, Ile-de-France, France

    Benoit Ho-Tin-Noé, PhD, works as a principal investigator at the Laboratory for Vascular Translational Science (Inserm Unit1148, Paris Cité University) in Paris. After completing his PhD in Hemostasis and Vascular Biology during which he studied the mechanisms of cellular plasminogen activation, he joined the laboratory of Dr Denisa Wagner in 2006, where he worked for 3 years as a postdoctoral fellow. There, he participated in a series of studies on the role of platelets in the maintenance of vascular integrity in inflamed organs and solid tumors. He was recruited in 2009 as a tenured researcher by the French National Institute of Health & Medical Research (INSERM) to work in a cardiovascular research academic laboratory in Paris (The Laboratory for Vascular Translational Science).
    In line with his PhD and postdoctoral work, he has focused his research on studying the functions of platelets in various inflammatory settings and on investigating the pathophysiology of thrombotic diseases. During the last years, his group has provided evidence that:
    - platelets exert a dual role in inflammation: while they promote leukocyte recruitment and activation, they also continuously repair leukocyte-mediated vascular injury in inflamed organs and solid tumors
    - microvascular thromboinflammation in ischemic stroke is a direct and early response to large vessel occlusion that impairs downstream reperfusion following mechanical arterial recanalization and that can be targeted pharmacologically for improved reperfusion therapy
    - extracellular DNA, von Willebrand factor, and platelets form tPA resistant domains in thrombi recovered from ischemic stroke patients
    His current research projects aim at studying 1) the role of platelet/leukocyte interactions in microvascular injury at the acute phase of ischemic stroke, 2) the efficacy of various adjuvant therapies for improved tPA-mediated thrombolysis of ischemic stroke thrombi, and 3) he participation of platelets in the tumor microvascular and inflammatory microenvironment.

    Presentation(s):